90 related articles for article (PubMed ID: 35019523)
1. Self-Assembled Plasmid Delivery System for PPM1D Knockout to Reverse Tumor Malignancy.
Ren XH; He XY; Liu BY; Xu C; Cheng SX
ACS Appl Bio Mater; 2020 Nov; 3(11):7831-7839. PubMed ID: 35019523
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Liu BY; He XY; Zhuo RX; Cheng SX
J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
[TBL] [Abstract][Full Text] [Related]
4. A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
Liu BY; He XY; Xu C; Xu L; Ai SL; Cheng SX; Zhuo RX
Biomacromolecules; 2018 Jul; 19(7):2957-2968. PubMed ID: 29617556
[TBL] [Abstract][Full Text] [Related]
5. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851
[TBL] [Abstract][Full Text] [Related]
6. Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Liu BY; He XY; Zhuo RX; Cheng SX
Nanoscale; 2018 Dec; 10(45):21209-21218. PubMed ID: 30417194
[TBL] [Abstract][Full Text] [Related]
7. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
[TBL] [Abstract][Full Text] [Related]
8. A novel dual-targeting delivery system for specific delivery of CRISPR/Cas9 using hyaluronic acid, chitosan and AS1411.
Khademi Z; Ramezani M; Alibolandi M; Zirak MR; Salmasi Z; Abnous K; Taghdisi SM
Carbohydr Polym; 2022 Sep; 292():119691. PubMed ID: 35725215
[TBL] [Abstract][Full Text] [Related]
9. A Multifunctional Delivery System for Remodulating Cell Behaviors of Circulating Malignant Cells to Prevent Cell Fusion.
Han D; He XY; Huang Y; Gao M; Guo T; Ren XH; Liao XR; Chen XS; Pang X; Cheng SX
Adv Sci (Weinh); 2023 Oct; 10(29):e2303309. PubMed ID: 37590231
[TBL] [Abstract][Full Text] [Related]
10. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy.
Ren XH; Xu C; Li LL; Zuo Y; Han D; He XY; Cheng SX
J Control Release; 2022 Mar; 343():645-656. PubMed ID: 35157940
[TBL] [Abstract][Full Text] [Related]
11. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene.
Ma K; Li W; Zhu G; Sun S; Chi H; Yin Y; Diao H; Xing XJ; Guo Z; Wang L; Xu W; Cui C; Xu J
Biomed Pharmacother; 2021 Oct; 142():112061. PubMed ID: 34449313
[TBL] [Abstract][Full Text] [Related]
12. Retro-inverso d-peptide-modified hyaluronic acid/bioreducible hyperbranched poly(amido amine)/pDNA core-shell ternary nanoparticles for the dual-targeted delivery of short hairpin RNA-encoding plasmids.
Gu J; Chen X; Fang X; Sha X
Acta Biomater; 2017 Jul; 57():156-169. PubMed ID: 28442415
[TBL] [Abstract][Full Text] [Related]
13. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
14. A multi-functional macrophage and tumor targeting gene delivery system for the regulation of macrophage polarity and reversal of cancer immunoresistance.
He XY; Liu BY; Xu C; Zhuo RX; Cheng SX
Nanoscale; 2018 Aug; 10(33):15578-15587. PubMed ID: 30090893
[TBL] [Abstract][Full Text] [Related]
15. Self-assembly of an aptamer-decorated chimeric peptide nanocarrier for targeted cancer gene delivery.
Dehghani S; Alibolandi M; Tehranizadeh ZA; Oskuee RK; Nosrati R; Soltani F; Ramezani M
Colloids Surf B Biointerfaces; 2021 Dec; 208():112047. PubMed ID: 34418722
[TBL] [Abstract][Full Text] [Related]
16. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
17. Gene-editing by CRISPR-Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression.
Wang CS; Chang CH; Tzeng TY; Lin AM; Lo YL
Nanoscale Horiz; 2021 Sep; 6(9):729-743. PubMed ID: 34323910
[TBL] [Abstract][Full Text] [Related]
18. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH
Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231
[TBL] [Abstract][Full Text] [Related]
19. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
20. A Nucleic Acid/Gold Nanorod-Based Nanoplatform for Targeted Gene Editing and Combined Tumor Therapy.
Tang W; Han L; Lu X; Wang Z; Liu F; Li Y; Liu S; Liu S; Tian R; Liu J; Ding B
ACS Appl Mater Interfaces; 2021 May; 13(18):20974-20981. PubMed ID: 33909408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
